(Q33871466)

English

Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics

scientific article published in 2000

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

pharmacodynamics

1 reference

based on heuristic

inferred from title

author name string

Nightingale CH

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

1 March 2000

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

20

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

245-256

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic-resistant bacteria that infect man and compromise antimicrobial chemotherapy?

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Structure-activity and structure-side-effect relationships for the quinolone antibacterials

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Expanded activity and utility of the new fluoroquinolones: a review

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Bactericidal properties of moxifloxacin and post-antibiotic effect.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.20.4.245.34880

21 January 2018

Identifiers

10.1592/PHCO.20.4.245.34880

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33871466&oldid=2143854078"